The MyRisk Hereditary Cancer Test helps you make the decisions that matter most

Knowing your patient’s hereditary cancer risk is critical when it comes to making treatment decisions. Blending both genetic test status and personal cancer family history, the MyRisk Hereditary Cancer Panel represents the next generation of hereditary cancer risk testing. MyRisk is here to help you determine the right treatment for your patients with a report including comprehensive results and a guideline-based Medical Management Tool.


3 out of 4 patients pay $0


Average turnaround time is 7-14 days


We make genetic testing simple for your patients and your practice

The mid adult female doctor reviews her patient's records on her computer in her office.

Myriad is your trusted advisor

  • 27+ years of experience in hereditary cancer testing
  • Analytically validated high-throughput sequencing
  • Industry leading variant classification program
  • Lifetime commitment to variant classification & result updates

Commitment to providing broad patient access

  • Myriad works directly with patients to provide up front clarity and resolve questions about cost (cost estimator coming soon)
  • Affordability options personalized to patients’ unique needs
  • 97% of private insurance have coverage for testing
  • Pre-test counseling services to educate patients on HC testing (post-test coming soon)
  • 90% of patients have or will qualify for a payment of $100 or less
Nurse explaining good news to female patient

MyRisk is identifying risk for your patients

MyRisk Hereditary Cancer Panel

Multi-gene panel determines hereditary cancer risk associated with 11 cancer sites:

  • Breast
  • Ovarian
  • Colorectal
  • Endometrial
  • Skin
  • Pancreatic
  • Gastric
  • Prostate
  • Renal
  • Lung
  • Endocrine

MyRisk Management Tool (MMT)

The MyRisk test report provides recommendations for managing patients with both positive AND negative genetic results. Every report includes the MyRisk Genetic Result and a personalized MyRisk Medical Management Tool based on professional society guidelines.


Myriad CompleteTM

Your partner in patient care

With Myriad Complete, we support you and your patients throughout the genetic screening process:

    • Pre-screen education
    • Transparent pricing and billing support
    • Clear results reporting
    • Post-screen education

These solutions allow for seamless integration of Myriad Genetics’ prenatal screens into your clinical care routines to help patients better understand and benefit from their results.

Cropped shot of businesspeople shaking hands during a meeting in an office

Data-sharing, discovery and insights

Patients and providers are at the center of our mission to make genetic testing and data-driven medical information more widely available. Beginning in Spring 2023, we will be sharing clinically impactful hereditary cancer and prenatal data submissions with the ClinVar public database. We will continue to identify ways to leverage our datasets as we work to advance health and well-being for all, and enable healthcare providers to better detect, treat, and prevent disease.

Why Choose Myriad?


Scientific publications consisting of clinically meaningful information have been published in peer reviewed journals over the past 5 years

$341.7 Million

Invested in research over the past 5 years


Academic institutions have collaborated with Myriad to help advance medical and scientific knowledge and healthcare overall. You can view a list of these institutions here.

Myriad's family of products

2022 Myriad, the Myriad logo, MyriadPro, the MyriadPro logo, Myriad MyRisk Hereditary Cancer, the Myriad MyRisk Hereditary Cancer logo, BRACAnalysis, the BRACAnalysis logo, Prolaris, the Prolaris logo, Foresight, the Foresight logo, GeneSight, the GeneSight logo, MyChoice, MyChoice logo, Endopredict, the Endopredict logo, Prequel, the Prequel logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions.